Home › Trial NCT07011654
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
- Trial IDNCT07011654
- StatusRecruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment31
- Start date2025-09-19
- ConditionsMetastatic Triple-Negative Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.